Advaxis, Inc. Common Stock, also called Advaxis, is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. Read More It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. The listed name for ADXS is Advaxis, Inc. Common Stock.